PGP and cancer: In addition, we demonstrated that low-dose crizotinib had concentration- and time-dependent sensitizing effects on P-gp-overexpressing drug-resistant KBV20C cells, suggesting that lower doses and a shorter duration of crizotinib treatment are sufficient to sensitize drug-resistant cancer cells.